Active, not recruitingPhase 3NCT05456425

A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium

Studying Body integrity dysphoria

Last synced from ClinicalTrials.gov May 5, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Cloudbreak Therapeutics, LLC
Intervention: CBT-001(drug)
Enrollment: 660 target
Eligibility: 12 years · All sexes
Timeline: 2022 – 2027

Study locations (30)

Trinity Research Group, Dothan, Alabama, United States
Horizon Eye Specialists & LASIK Center, Sun City, Arizona, United States
West Coast Eye Institute, Bakersfield, California, United States
Global Research Mangement, Glendale, California, United States
Inland Eye Specialists, Hemet, California, United States
Eye Research Foundation, Newport Beach, California, United States
Shultz Chang Vision, Northridge, California, United States
North Bay Eye Associates INC, Petaluma, California, United States
Santa Barbara Eye Care, Santa Barbara, California, United States
Advanced Research; LLC, Deerfield Beach, Florida, United States
Bruce A. Segal, MD, Delray Beach, Florida, United States
International Research Center, Tampa, Florida, United States
The Eye Care Institute, Louisville, Kentucky, United States
Center for Sight, Henderson, Nevada, United States
Vance Thompson Vision, Sioux Falls, South Dakota, United States
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05456425 on ClinicalTrials.gov

Other trials for Body integrity dysphoria

Additional recruiting or active studies for the same condition.

See all trials for Body integrity dysphoria →

← Back to all trials